Over the past few years, Stevanato Group has strategically expanded its drug delivery systems team and broadened its offering to include capabilities and services as an integrated solutions provider. The company is now offering a broader range of solutions to its pharmaceutical partners, such as contract manufacturing of devices, which is key, to produce their drug delivery systems.
Boasting a one-stop-shop approach enabled us to collaborate in a more meaningful way on a higher number and variety of programs. We have explored the combination product space extensively, focusing on four categories of drug delivery systems: pen-injectors, auto-injectors, wearables, and inhalers.
With regards to pen injectors, Stevanato Group is developing a new device platform based on Haselmeier’s variable-dose pen injection technology, Axis-D into the diabetes space for the delivery of insulin/insulin analog products and GLP-1s.
For auto-injectors, SG EZ-be Pod® is a proprietary cartridge-based wearable device for adjustable regimens.
Finally, on inhalers, Stevanato Group is working with ICONOVO on a capsule-based inhaler system for asthma and COPD.
- SG Alina® Pen Injector
- A platform pen injector for diabetes care, exclusively based on IP and technology licensed from Haselmeier
- SG EZ-be Pod® Wearable
- Our proprietary wearable device designed to maximize patient comfort utilizing innovative technology to optimize the compactness of the device
- ICOcap Inhaler
- An easy-to-use dry powder inhaler with improved handling features licensed from inhalation specialty firm Iconovo